Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M767Revenue (TTM) $M6.4Net Margin (%)-789.3Altman Z-Score-5.3
Enterprise Value $M804EPS (TTM) $-0.5Operating Margin %-767.0Piotroski F-Score2
P/E(ttm)--Beneish M-Score-0.1Pre-tax Margin (%)-789.3Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-3.9Quick Ratio7.8Cash flow > EarningsN
Price/Sales1125-y EBITDA Growth Rate %-1.6Current Ratio7.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-44.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M142ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ZIOP

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ZIOP is held by these investors:

ZIOP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BELBEL CAESAR JCOO, CLO, and Secretary 2015-11-19Sell153,333$12.84-57.94view
LEBEL FRANCOISExecutive Vice President R&D 2015-06-09Sell50,000$10.12-46.64view
BRENNAN MURRAYDirector 2015-06-04Sell40,000$9.7-44.33view
Lafond Kevin GVice Pres., Treasurer, & CAO 2015-06-03Sell57,500$9.65-44.04view
KIRK RANDAL JDirector, 10% Owner 2015-02-09Buy1,440,000$8.75-38.29view
KIRK RANDAL JDirector, 10% Owner 2013-10-29Buy2,857,143$3.554.29view
KIRK RANDAL JDirector, 10% Owner 2012-01-20Buy1,923,075$5.23.85view
KIRK RANDAL JDirector, 10% Owner 2011-08-23Buy38,294$4.998.22view
KIRK RANDAL JDirector, 10% Owner 2011-08-22Buy461,646$4.929.76view
Fowler WycheDirector 2011-08-10Buy5,000$5.194.05view

Press Releases about ZIOP :

Quarterly/Annual Reports about ZIOP:

News about ZIOP:

Articles On GuruFocus.com
ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex Oct 16 2017 
ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology Oct 12 2017 
ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Office Sep 28 2017 
ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recu Sep 18 2017 
ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017 
ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit Sep 01 2017 
ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activi Jul 31 2017 
ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call Jul 24 2017 
ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Gliob Jun 05 2017 
ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference Jun 02 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat